Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hyperlipoproteinemias

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    February 2024
  1. STONE NJ, Blum C
    If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
    Circulation. 2024;149:427-429.
    PubMed    


    January 2024
  2. SANTOS RD, Cuchel M
    LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Circulation. 2024;149:363-366.
    PubMed    


    November 2023
  3. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
    BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
    Circulation. 2023;148:1764-1777.
    PubMed     Abstract available


  4. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    PubMed     Abstract available


    October 2023
  5. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    PubMed     Abstract available


  6. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    PubMed     Abstract available


    September 2023
  7. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.
    PubMed    


  8. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.
    PubMed    


  9. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    PubMed    


    July 2023
  10. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    PubMed     Abstract available


    May 2023
  11. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    PubMed    


    April 2023
  12. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    PubMed     Abstract available


    February 2023
  13. PAN C, Herrero-Fernandez B, Borja Almarcha C, Gomez Bris R, et al
    Time-Restricted Feeding Enhances Early Atherosclerosis in Hypercholesterolemic Mice.
    Circulation. 2023;147:774-777.
    PubMed    


    October 2022
  14. SHOTWELL MK, Vorla M, Kalra DK
    Very High Cholesterol Mimicking Homozygous Familial Hypercholesterolemia.
    Circulation. 2022;146:1182-1188.
    PubMed    


    August 2022
  15. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    PubMed     Abstract available


    May 2022
  16. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    PubMed     Abstract available


    February 2022
  17. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    PubMed     Abstract available


    June 2021
  18. KUEHN BM
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.
    PubMed    


    March 2021

  19. Correction to: Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
    Circulation. 2021;143:e799.
    PubMed    


    November 2020
  20. KULLO IJ
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.
    PubMed    


    October 2020
  21. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.
    PubMed    


    November 2019
  22. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.